NYSE:ALife Sciences
Is New Esophageal Cancer Keytruda Test Approval Reshaping The Investment Case For Agilent Technologies (A)?
In March 2026, Agilent Technologies received U.S. Food and Drug Administration approval for its PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic to identify esophageal or gastroesophageal junction carcinoma patients (CPS = 1) who may be eligible for Merck’s KEYTRUDA (pembrolizumab) combination therapy.
This eighth KEYTRUDA-related indication for PD-L1 IHC 22C3 pharmDx strengthens Agilent’s role in precision oncology by broadening its companion diagnostic...